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Doctors’ reported loss of autonomy in the current policy climate and the 
subsequent deprofessionalisation of medicine can be attributed to many factors. The 
pharmaceutical industry accounts for a large proportion of healthcare costs, with the 
professional relationship between the industry and medical profession raising ethical 
concerns. Developing potentially life-saving products and potentiating scientific 
advances are some of the many good attributes of the pharmaceutical industry. The 
dependence of medical care on the production of pharmaceuticals is undeniable. 
However, it could be argued that the pharmaceutical industry takes advantage of 
this relationship, fuelled by financial motive. Conversely, there could be a complex 
interplay of factors driving a power imbalance in the pharma/clinical relationship. 
By reviewing literature in the field, this viewpoint article explores these multifaceted 
factors.
The British Student Doctor, 2019;3(2):9-18
doi: 10.18573/bsdj.49 
Discussion
The British Student Doctor
Volume 3, No. 2 (2019)
10
bsdj.org.uk
Medical students are to enter a profession at the forefront of improving the health 
of individuals and populations. Scientific innovation, particularly in the field of the 
pharmaceutical industry, is one of the exciting ways through which physicians are able 
to practise medicine through prescribing. However, with an increasing array of drugs 
available, it is important for newly qualified doctors to be able to navigate their way 
through pharmaceutical industry marketing to ensure optimal clinical practice. (1)
In the past, healthcare was dominated by a paternalistic approach, with people having 
little access to the medical knowledge held by doctors. (2) The advent of technology 
and a shift in attitude has resulted in a more informed public, who expect to be 
involved in decisions affecting their care. (3) For doctors, this means patients are 
possibly more accountable for their own health, but potentially less trusting of the 
medical profession. (3) (Haug, 1973) predicted professionals will lose "their monopoly 
over knowledge, public belief in their service ethos and expectations of work autonomy and 
authority over the client". (4)
Barriers that prevent the profession from carrying out its moral duty to improve the 
health of general society could reduce professional autonomy. The industry may 
encourage reliance on prescribed medication, thereby changing the way society 
responds to health problems and creating a market for products beyond health needs. 
(5) This article will explore the extent of the influence of the pharmaceutical industry 
on the medical profession. The Government and governing bodies have an impact on 
drug availability, as well as prescribing practitioners. Market forces, patient demand 
and drug development costs may justify its presence and influence in society. 
The Government
It could be argued that governmental policy encourages pharmaceutical influence 
over the medical profession. Foucault states "the first task of the doctor is political: the 
struggle against disease must begin with a war against bad government". The Government 
negotiates with the pharmaceutical industry to decide the availability of patented or 
generic drugs for prescription, as well as enforcing caps and budget restrictions on the 
profession. (6) Most recently, The National Institute for Health and Care Excellence 
(NICE) has set a cap on drugs costing more than 20 million pounds a year, which is a 
breach of a pledge made in the Conservative Party’s manifesto. (7) The Government 
also introduced General Practice budgets in 1991 as an attempt to contain growth in 
NHS expenditure on prescribed drugs. (8) Therefore, the Government may actually 
be a driver of the pharmaceutical industry’s profits in the UK.
Conversely, 2009 Patient Access Schemes have been introduced, offering price 
reductions on drugs which were unlikely to meet NICE’s cost-effectiveness criteria. 
(9) Therefore, the presence of governmental policy and evidence-based medicine 
could contain the industry, protecting the professional power of the medical doctor. 
NHS and NICE
NICE is an important source of guidance for the use of health technologies within 
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the NHS and considers both the medical and economical indications. Therefore, 
NICE ultimately determines the influence of the pharmaceutical industry. The NHS 
Constitution states patients have the "right to drugs and treatments recommended by NICE if 
their doctor believes they are clinically appropriate". The NHS is therefore legally obliged to 
fund and resource medicines recommended by a NICE technology appraisal within 
three months of the published appraisal. (10,11) This legal obligation empowers the 
pharmaceutical industry to create drugs, which they know will have to be provided (if 
clinically appropriate). It may also give patients a sense of entitlement to medication 
that may not be commonly prescribed, for instance by lacking an evidence-base for its 
efficacy. Patients may feel they can challenge or pressurise their doctor into prescribing 
medications due to the presence of the publicly funded NHS through general taxation. 
Conversely, NICE may be enabling the pharmaceutical industry. The World Health 
Organisation (WHO) Report was critical of the pharmaceutical industry’s influence on 
NICE, particularly expressing that manufacturers should not be members of the drug 
appraisal committee. (12) By allowing manufacturers into this committee, NICE could 
be influenced to approve drugs endorsed by those manufacturers. This may undermine 
the regulatory system in place for NHS prescribing and potentially take advantage of 
NICE’s position in developing public health guidance, with guidelines being shaped by 
the financial interests of pharmaceutical industry shareholders.
The role of NICE could be challenged with the impending exit of the United 
Kingdom from the European Union. Currently, NICE is a lead partner in the 
European Network for Health Technology Assessment and therefore has a global 
influence. Although there is much uncertainty regarding the details of this at present, 
there will be relocation of the European Medicines Agency away from London. This 
will affect the evidence base for Health Technology Assessments due to less access to 
European research funding, as well as possibly increasing the cost of medicines and 
healthcare due to the expense of doing business as a small country. (13)
It can be seen that the availability of possibly life-saving medication has become 
increasingly dependent on economic factors, especially in a resource-poor public-
sector climate. It is considered a doctor’s decision to recommend treatment if deemed 
appropriate, but there are several notable cases where such clinical decisions have been 
undermined or delayed. Notably, NICE rejected trastuzumab emtansine (Herceptin) 
for use in the NHS for advanced breast cancer in 2015 for the sole reason of it being 
too expensive. The drug was reinstated after a deal was made with the manufacturer 
Roche. (14) The drug lumacaftor-ivacaftor (Orkambi) for cystic fibrosis has also been 
denied for reasons of cost-effectiveness, despite doctors predicting possible benefits for 
over 3000 patients, with reductions in hospital admissions and antibiotic use. (15, 16) 
Prescribing patterns
It may be the medical profession itself encouraging the pharmaceutical industry. 
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Medication costs the NHS over 7 billion pounds a year. (17) According to NHS 
Digital “In 2016 there were 1,104.1 million items dispensed, which is an increase of 1.9 per cent 
(20.5 million) on the number dispensed in 2015”. (18) In Britain, increased prescribing 
powers have been granted to nurses as they are allowed to prescribe independently 
in the community, within their area of competence or as part of an agreed plan by a 
doctor. (19) This could result in a greater number of drugs being issued to patients. 
Liberal prescribing patterns encourage the pharmaceutical industry, creating demand 
and financial motive to produce more medication. In doing so, the NHS is promoting 
an ideology that drugs can solve health problems as opposed to targeting the cause of a 
disease through prevention strategies. Although general health in society has improved 
over time, this has not been largely accounted for by the greater use of medicines, 
therefore proving the theory that drugs do not cure disease. (20)
Evidence-based medicine
The use of scientific research in clinical practice through evidence-based medicine 
is well-established in healthcare through clinical guidelines. This uses scientific 
evaluation of research literature to guide clinicians on  how to practise medicine. (21) 
There is a correlation between medical advances and professional decline. This is due 
to the automation of medical procedures, such as using sound waves instead of scalpels 
to treat kidney stones, which threatens physicians as 'operators' as opposed to masters of 
their technology. (22)
The presence of evidence-based guidelines could deprofessionalise medicine by taking 
away a clinician’s choice and pressurising them to practise medicine in a particular 
way. This could work in the favour of pharmaceutical companies, especially when 
using evidence in clinical trials.
The pharmaceutical industry is in a unique position as it can use scientific evidence 
to serve its own interests, especially in the pre-approval stage of drug development.  
Initial drug testing is carried out by laboratory scientists or pharmacologists, employed 
by pharmaceutical companies themselves. This means they could selectively use the 
information found when seeking approval for new drugs. (23) It is therefore important 
for professionals to carefully consider information supplied by drug companies and the 
media. 
Pharmaceutical companies can also influence doctors to prescribe specific drugs based 
on incentives, such as free samples. This could lead to a loss of trust and autonomy in 
the profession. The industry is able to educate and advise on the latest drugs, although 
this information is unregulated. Educating prescribers is important, however ensuring 
this information is accurate and balanced will allow professionals to make well-
informed decisions. (24) 
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Market forces
There is a rise of corporatisation within healthcare, with greater access to private 
healthcare in the UK than ever before. (6) This could create a societal divide in terms 
of those who receive medication, encouraging a feeling of entitlement to medication 
regardless of what the doctor thinks. 
It was recognised that biologic drug spending was rising; biosimilars were therefore 
reverse-engineered to reduce costs. (25) It may be that high drug cost is temporary 
and will be driven down to become more affordable for the NHS. Market changes are 
expected and may be a challenge to the medical profession that it will have to adapt and 
adjust to accordingly. 
An economic evaluation of biologics suggests acceptable cost-effectiveness in the long-
term due to stabilising disease to reduce costly inpatient surgery care, which accounts 
for "44% of the lifetime costs for a typical patient" with Crohn’s disease. (26) This justifies the 
expense of these drugs, while also proving a positive effect to society.
Some medication patented in the developed world is copied in developing countries, 
where patent rights of pharmaceutical products are not protected. (27) Therefore, 
manufacturers who have spent money on developing these products are outcompeted 
when it comes to selling them. This is troublesome to manufacturers’ profits, although 
perhaps enables the medical profession as drugs can be provided at a fairer price to 
society.
Research and development
Drug research and development (R&D) is often expensive and timely, which means 
companies often have to charge high prices to the medical profession to cover their 
costs. The pharmaceutical industry may use this financial motive to influence the 
prescription of certain medications.
It can take 10-15 years for drug approval after multiple phases of trials. Data conducted 
by pharmaceutical manufacturers is extrapolated from these trials and applied to the 
population, although the majority of trials are conducted on healthy, young sample 
groups. Doses in trials are often high as manufacturers need to prove their drug is 
effective, as opposed to finding the lowest possible therapeutic dose. (23) It may be 
tempting to omit or manipulate data that could negatively affect trial results; this may 
not become apparent until after drug approval, adversely affecting patients. 
An example concerns the risk of suicidality in adolescents taking selective serotonin 
reuptake inhibitor (SSRI) antidepressants, such as fluoxetine and paroxetine, coming to 
light years after drug approval. Aggressive behaviour, restlessness and increased hostility 
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in children and adolescents were described, with some reports showing cases of 
violence and murder. (28) For paroxetine in particular, drug companies retrospectively 
noted that for adults of all ages with depression, the frequency of suicidal behaviour 
was higher in patients (0.32%) compared to those treated with placebo (0.05%). (29)
There was a noticeable discrepancy between published and unpublished trials, which 
was shown in a 2004 UK review using Medicine and Healthcare products Regulatory 
Agency data. Under-reporting of this side effect was found to be due to limitation in 
the design of clinical trials, such as response-based selection bias and insufficient lead-
in periods. (28) Therefore, it is important to be wary of published trial information, 
with clinical study reports being far more reliable in determining the risk of serious 
harm in prescribed medications.
R&D costs are estimated by industry-funded studies at £1.15 billion per drug. (30) 
It is difficult to ascertain whether drug prices are justified or whether they are a 
result of pharmaceutical greed. Scannell et al. (31) attributes the high production 
cost to a decline in R&D efficiency, possibly due to overcautious regulation of the 
industry. It was noted that trials often fail early due to the absence of a drug’s positive 
effect in trials of low patient numbers, therefore increasing costs in the long term. 
Pharmaceutical financial motive may therefore negatively influence the medical 
profession.
The future
The medical profession relies on the pharmaceutical industry; instead of fighting 
against commercialism, working together may be a solution to the issues faced. This 
could be carried out through transparency in research and clinical endeavours. It 
may be more applicable to influence demand for pharmaceuticals via prescribing 
doctors. (32) The industry could work with hospital consultants and GPs to identify 
medication demand. Patients do not have the power to obtain drugs themselves 
without a prescription. Giving control back to the doctor through identifying 
prescribing needs in their experience and feeding this back to drug companies could 
be a solution. This will empower the profession, while still ensuring manufacturers 
have products to sell, as medication does of course play a key role in healthcare 
provision. 
Further regulation of the pharmaceutical industry globally would improve efficiency 
and availability of life-changing medication to all populations. Improving productivity 
would drive down cost prices and enable the future viability of the healthcare system. 
(31) More realistic government funding to the pharmaceutical industry to match the 
increase in production costs for pharmaceutics would relieve financial pressures on 
manufacturers. Furthermore, independently funded and transparent research could be 
carried out to ensure patient safety. (23)
Conclusion
As a student entering the profession, it is important to be aware of the changing 
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nature of what it means to be a medical professional in society. This ultimately means 
acknowledging that the profession is dynamic, influenced by market forces and 
governed in a way that influences clinical practice. Considering public perception of 
medication, as well as their view of professionals, is imperative in making decisions on 
clinical practice. The pharmaceutical industry does have the power to influence the 
medical profession, however doctors still have overriding responsibility and a duty of 
care on medication prescribed to their patients.
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